Table 3 Summary of the frequency of methylation of the genes in lung tumors based of their main clinicopathologic variables.
From: Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer
Gene | Overall (%) | Histology (%) | Differentation Grade (%) | Tumor stage (%) | ||||
|---|---|---|---|---|---|---|---|---|
Methylation n = 54 | SCC n = 21 | ADC n = 32 | Good n = 11 | Moderate n = 16 | Poor n = 27 | Local n = 22 | Advanced n = 32 | |
PRDM2 | 22 (40.7) | 10 (45.4) | 12 (37.5) | 21 (45.6) | 0 (0) | 12 (44.4) | 10 (45.4) | 12 (37.5) |
RUNX3 | 23 (42.5) | 13 (59.1) | 10 (31.2) | 19 (41.3) | 2 (33.3) | 10 (37.0) | 13 (59.1) | 10 (31.2) |
RARB | 20 (37) | 8 (36.4) | 12 (37.5) | 17 (36.9) | 3 (50.0) | 10 (37.0) | 8 (36.4) | 12 (37.5) |
HLTF | 8 (14.8) | 1 (4.5) | 7 (21.9) | 8 (17.4) | 0 (0) | 7 (25.9) | 1 (4.5) | 7 (21.9) |
HLT-2 | 17 (31.5) | 9 (40.9) | 8 (25.0) | 14 (30.4) | 2 (33.3) | 10 (37.0) | 9 (40.9) | 8 (25.0) |
SCGB3A1 | 27 (50.0) | 15 (68.2) | 12 (37.5) | 24 (52.2) | 2 (33.3) | 15 (55.5) | 15 (68.2) | 12 (37.5) |
SCGB3A1-2 | 17 (31.5) | 12 (54.5) | 5 (15.6) | 12 (26.0) | 4 (66.7) | 9 (33.3) | 12 (54.5) | 5 (15.6) |
ID4 | 25 (46.3) | 12 (54.5) | 13 (40.6) | 23 (50.0) | 1 (1.7) | 12 (44.4) | 12 (54.5) | 13 (40.6) |
ID4-2 | 11 (20.4) | 5 (22.7) | 6 (18.7) | 10 (21.7) | 1 (1.7) | 7 (25.9) | 5 (22.7) | 6 (18.7) |
TWIST1 | 21 (38.9) | 9 (40.9) | 12 (37.5) | 19 (41.3) | 2 (33.3) | 10 (37.0) | 9 (40.9) | 12 (37.5) |
SFRP4 | 10 (18.5) | 7 (31.8) | 3 (9.4) | 9 (19.5) | 1 (1.7) | 5 (18.5) | 7 (31.8) | 3 (9.4) |
SFRP4-2 | 16 (29.6) | 11 (50.0) | 5 (15.6) | 12 (26.0) | 3 (50.0) | 8 (29.6) | 11 (50.0) | 5 (15.6) |
DLC1 | 22 (40.7) | 12 (54.5) | 10 (31.2) | 18 (39.1) | 3 (50.0) | 13 (48.1) | 12 (54.5) | 10 (31.2) |
DLC1-2 | 27 (50.0) | 15 (68.2) | 12 (37.5) | 21 (45.6) | 5 (83.3) | 14 (51.8) | 15 (68.2) | 12 (37.5) |
SFRP5 | 17 (31.5) | 8 (36.4) | 9 (28.1) | 15 (32.6) | 2 (33.3) | 10 (37.0) | 8 (36.4) | 9 (28.1) |
SFRP5-2 | 12 (22.2) | 6 (27.3) | 6 (18.7) | 9 (19.6) | 2 (33.3) | 8 (29.6) | 6 (27.3) | 6 (18.7) |
BNIP3 | 24 (44.4) | 12 (54.5) | 12 (37.5) | 20 (43.5) | 2 (33.3) | 13 (48.1) | 12 (54.5) | 12 (37.5) |
H2AFX | 10 (18.5) | 5 (22.7) | 5 (15.6) | 9 (19.5) | 1 (1.7) | 6 (22.2) | 5 (22.7) | 5 (15.6) |
H2AFX-2 | 9 (16.7) | 6 (27.3) | 3 (9.4) | 8 (17.4) | 1 (1.7) | 5 (18.5) | 6 (27.3) | 3 (9.4) |
CCND2 | 26 (48.1) | 13 (59.1) | 13 (40.6) | 22 (47.8) | 3 (50.0) | 15 (55.5) | 13 (59.1) | 13 (40.6) |
CCND2-2 | 29 (53.7) | 14 (63.6) | 15 (46.9) | 25 (54.3) | 4 (66.7) | 15 (55.5) | 14 (63.6) | 15 (46.9) |
CACNA1G | 21 (38.9) | 12 (54.5) | 9 (28.1) | 19 (41.3) | 1 (1.7) | 12 (44.4) | 12 (54.5) | 9 (28.1) |
TGIF | 10 (18.5) | 5 (22.7) | 5 (15.6) | 9 (19.5) | 1 (1.7) | 6 (22.2) | 5 (22.7) | 5 (15.6) |
BCL2 | 8 (14.8) | 4 (18.2) | 4 (12.5) | 8 (17.4) | 0 (0) | 5 (18.5) | 4 (18.2) | 4 (12.5) |
CACNA1A | 18 (33.3) | 11 (50.0) | 7 (21.9) | 13 (28.3) | 4 (66.7) | 8 (29.6) | 11 (50.0) | 7 (21.9) |
TIMP3 | 10 (18.5) | 7 (31.8) | 3 (9.4) | 9 (19.6) | 1 (1.7) | 5 (18.5) | 7 (31.8) | 3 (9.4) |
TIMP3-2 | 11 (20.4) | 7 (31.8) | 4 (12.5) | 9 (19.6) | 1 (1.7) | 6 (22.2) | 7 (31.8) | 4 (12.5) |